%0 Journal Article %T PD-L1 as a biomarker in NSCLC: challenges and future directions %A Mathew, Matthen %A Safyan, Rachael A. %A Shu, Catherine A. %J Annals of Translational Medicine %D 2017 %B 2017 %9 %! PD-L1 as a biomarker in NSCLC: challenges and future directions %K %X The Food and Drug Administration (FDA) approval of immune checkpoint inhibitors has dramatically changed treatment paradigms for patients with advanced-stage or metastatic non-small cell lung cancer (NSCLC). Despite significant improvements in survival, the majority of NSCLC patients fail to respond to checkpoint inhibitors, notably antibodies targeting programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1), and uncertainties remain regarding how best to use these therapies in clinical practice. Given the risk of immune-related and other adverse effects associated with treatment, there is a need to identify biomarkers to predict which patients will and will not benefit. %U https://atm.amegroups.org/article/view/16060 %V 5 %N 18 %P 375 %@ 2305-5847